AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02316262 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted Muscle Reinnervation
Description: Targeted reinnervation (TR) is a surgical procedure originally designed to provide intuitive control of upper limb prostheses through transfers of residual nerves to otherwise redundant target muscle. Native motor innervation of the target muscle is cut, and the residual nerves-after excision of end-neuromas-are coapted to the motor end point of the motor nerve, close to its point of entry into the muscle. The central principle underlying the nerve transfers in TR surgery is to reestablish the function of the amputated nerve and allow intuitive, seamless prosthesis control.
Study NCT02735434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based ACT
Description: The guided internet program consists of 7 modules activated consecutively over a period of 12 weeks. The content is written psycho education, patient videos, audio-exercises and behavioural exposure exercises. The program is therapist-guided; hence all patients will receive support from primarily the same therapist during the 12 weeks.
Study NCT02735434 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based discussion forum
Description: The online discussion forum consists of 7 themes touching upon the impact of health anxiety and the patients own coping strategies. The themes are activated consecutively over a period of 12 weeks. The discussion forum is text-based, and only patients will participate in the discussion. The written discussions will be reviewed by a professional for ethical reasons. The discussion forum aims to control for the effect of attention and contacts to the health care system. After 9 months patients in the discussion forum are offered active treatment, but not as part of the research project.
Study NCT04012086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Our physical therapy program included a variety of different exercise modalities (aerobic exercises, treadmill training and exercise intervention program) performed under the supervision of a physiotherapist
Study NCT01177995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Network Intervention
Description: Social network leaders will communicate HIV prevention messages to members of their social networks.
Study NCT05809102 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: repair of flexor tendon in Zone II
Description: Repair of Zone II flexor tendon of the hand using minimal incisions instead of whole tendon exposure
Study NCT00479219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSI-953
Study NCT00479219 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02573545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Planning@IFE and Standard@IFE Software
Study NCT02573545 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MR Syngo (Numaris/4) software
Study NCT00741208 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Soy Isoflavone
Description: 50mg soy isoflavone supplement consumed twice daily for a total of 100mg of soy isoflavones per day.
Study NCT04482192 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic paravertebral block
Description: After ending pulmonary procedure, a pleural pouch created beside vertebral column, a catheter is inserted to the pouch for continuous infusion of 1% lidocaine for 3 postoperative days. Intravenous morphine sulfate (0.05mg/kg) was given as a rescue medication if the VAS ≥ 4.
Study NCT04482192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic analgesia
Description: Systemic analgesia (SA) group receive 1gm paracetamol and 30 mg ketorolac by intravenous infusion every 6 hours for 3 days. Intravenous morphine sulfate (0.05mg/kg) was given as a rescue medication if the VAS ≥ 4.
Study NCT00532246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raloxifene
Study NCT00532246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00752245 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dialysis during 4 hours
Description: Blood and dialysate sampling
Study NCT00752245 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dialysis during 6 hours
Description: Blood and dialysate sampling
Study NCT00752245 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dialysis during 8 hours
Description: Blood and dialysate sampling
Study NCT03592004 — intervention group
Intervention type: OTHER
Intervention: neoadjuvant chemotherapy
Description: neoadjuvant chemotherapy
Study NCT00869271 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tac + folfox4
Description: tac: oxaliplatin 100mg + fudr 1g + mmc 10mg~folfox4~Folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemotherapy(TAC) using oxaliplatin, fudr and mmc. Then begin folfox4 again.
Study NCT00869271 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Folfox4
Description: folfox4~Folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle
Study NCT05972798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Description: 2.2 g/d omega-3 PUFAs (1.2g EPA and 1g DHA per day) in patients with LLD
Study NCT05972798 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Soybean oil
Description: Soybean oil in patients with LLD
Study NCT01162720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short duration tourniquet
Description: Patients assigned to this arm will have the tourniquet applied during cement fixation of the prosthesis only (ie removed just prior to wound closure).
Study NCT05049473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m² IV. Day 1. Cycles: A1/A1\*, B1/B1\*, C1/A2\*, A2/B2\*, B2/A3\*, C2/B3\*. Two additional doses after 6 cycles in case of localized stage patients without CR after four cycles or advanced stage patients.
Study NCT05049473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 1500 mg/m² IV 24h-infusion. Day 2. Cycles: A1, B1, C1 (1000 mg/m² if patient in CR) , A2 (1000 mg/m² if patient in CR), B2 (1000 mg/m² if patient in CR) , C2 (1000 mg/m² if patient in CR) Methotrexate 500 mg/m² IV 24h-infusion. Day 2. Cycles: A1\*, B1\*, A2\*, B2\*, A3\*, B3\*
Study NCT05049473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 10 mg/m² PO or IV bolus. Days: 2 to 6. Cycles: A1/A1\*, B1/B1\*, C1/A2\*, A2/B2\*, B2/A3\*, C2/B3\*.
Study NCT05049473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iphosphamid
Description: Iphosphamid 800 mg/m² IV in 1 hour. Days: 2 to 6. Cycles: A1, A2 (500 mg/m² if patient in CR).~Iphosphamid 400 mg/m² IV in 1 hour. Days: 2 to 6. Cycles: A1\*.
Study NCT05049473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 2 mg IV bolus. Day 2. Cycles: A1, B1, A2, B2 Vincristine 1 mg IV bolus. Day 2. Cycles: B1\*, B2\*, B3\*
Study NCT05049473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide (VP16) 100 mg/m² IV in 1 hour. Days: 5, 6. Cycle: A1, A2. Etoposide (VP16) 250 mg/m² IV in 1 hour. Days: 5, 6. Cycle: C1, C2. Etoposide (VP16) 60 mg/m² IV in 1 hour. Days: 5, 6. Cycle: A1\*, A2\*, A3\*.
Study NCT05049473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 150 mg/m² IV in 1 hour every 12 hours. Days: 5, 6. Cycles: A1, A2 Cytarabine 2 g/m² IV in 3 hours every 12 hours. Day: 6. Cycle: C1 (1.5 g/m² if patient in CR), C2 (1.5 g/m² if patient in CR) Cytarabine 60 mg/m² IV in 1 hour every 12 hours. Days: 5, 6. Cycles: A1\*, A2\*, A3\*
Study NCT05049473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 200 mg/m² IV in 1 hour. Days 1 to 5. Pre-phase. Cyclophosphamide 200 mg/m² IV in 1 hour. Days 2 to 6. Cycles: B1, B2, B1\*, B2\*, B3\*
Study NCT05049473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 25 mg/m² IV in 15 min. Days 5 and 6. Cycles: B1/B1\*, B2, B2\*, B3\*
Study NCT05049473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vindesine
Description: Vindesine 3 mg/m2 (max 5 mg) IV bolus. Day 2. Cycles: C1, C2
Study NCT05049473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 30 mg IT. Days 2 and 6. Cycles A1, B1, A2, B2
Study NCT05049473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 12 mg IT. Day 1. Pre-phase Methotrexate 12 mg IT. Days 2 and 6. Cycles: A1, B1, A2, B2 Methotrexate 15 mg IT. Day 2. Cycles: A1\*, B1\*, A2\*, B2\*, A3\*, B3\*
Study NCT05049473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone 20 mg IT. Days 2 and 6. Cycles: A1, B1, A2, B2
Study NCT05049473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 60 mg/m2 PO or IV bolus. Days 1 to 5. Pre-phase.
Study NCT04234594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1203
Description: 6 mg/kg intravenous (IV) infusion only once，on the first day.
Study NCT04234594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vectibix®
Description: 6 mg/kg intravenous (IV) infusion only once，on the first day.
Study NCT03834714 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Near Infrared Light
Description: NIR Light Therapy will be administered with the Earlight Generation 1.4 device during 2 out of the 4 sessions. It will be administered to each ear individually for 30 minutes per ear.
Study NCT03834714 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Noise Stimulus
Description: Noise stimulus will be administered, open ear, to continuous broadband noise up to 25% of the allowable daily dose of noise per the AFI 48-127 Occupational Noise and Hearing Conservation Program.
Study NCT03834714 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Noise Stimulus
Description: Noise stimulus will be administered, open ear, to continuous broadband noise up to 25% of the allowable daily dose of noise per the AFI 48-127 Occupational Noise and Hearing Conservation Program.
Study NCT03834714 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Near Infrared Light
Description: Sham NIR Light Therapy will be administered with the Earlight Generation 1.4 device during 2 out of the 4 sessions. It will be administered to each ear individually for 30 minutes per ear.
Study NCT01048684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: Variation of mannitol dose
Study NCT01048684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Variation of mannitol dose
Study NCT02304354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: For rheumatoid arthritis, MabThera is given as two intravenous infusions of 1000 mg with a two-week interval between them. Patients usually respond to treatment within 16 to 24 weeks of initial treatment. After 24 weeks, treatment can be repeated depending on the patient's response.
Study NCT04284163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamification
Description: Teaching through gamification
Study NCT04284163 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional teaching
Description: Teaching through master lesson methodology
Study NCT02247232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-100
Study NCT02247232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04679948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Percoffedrinol®
Description: Tablet
Study NCT04679948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coumadin®
Description: Tablet
Study NCT04679948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antra MUPS®
Description: Gastro-resistant tablet
Study NCT04679948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam-ratiopharm®
Description: Oral solution
Study NCT04679948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: Film-coated tablet
Study NCT04081857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1810
Description: HGP1810: Vildagliptin/Metformin
Study NCT04081857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1704
Description: HCP1704: Vildagliptin/Metformin
Study NCT00623857 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc
Description: Daily oral supplementation with zinc, 10 mg, for an average of 60 weeks
Study NCT00623857 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamins and minerals other than zinc
Description: Daily supplementation with vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, iron, iodine, copper, selenium, magnesium and calcium; for an average of 60 weeks
Study NCT00623857 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamins plus zinc and other minerals
Description: Daily oral supplementation with zinc, vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, iron, iodine, copper, selenium, magnesium and calcium; for an average of 60 weeks
Study NCT00623857 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral supplementation with placebo for vitamins and all minerals; for an average of 60 weeks
Study NCT02614404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib combination therapy
Description: Imatinib plus dihydroartemisinin plus piperaquine
Study NCT02614404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine
Description: Standard of care
Study NCT02540967 — intervention group
Intervention type: DRUG
Intervention: Gadobutrol (Gadavist/Gadovist, BAY86-4875)
Description: Gadovist dosage following summary of product characteristics
Study NCT00055497 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Double-blind (DB) adalimumab placebo
Description: Double-blind nonactive matching subcutaneous injection
Study NCT00055497 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DB adalimumab 40 mg eow
Description: Double-blind adalimumab 40 mg every other week by subcutaneous injection
Study NCT00055497 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DB adalimumab 40 mg ew
Description: Double-blind adalimumab 40 mg every week by subcutaneous injection
Study NCT00055497 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OL adalimumab 40 mg
Description: Open-label adalimumab every other week or every week by subcutaneous injection
Study NCT03613688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Deepure
Description: Pu'erh Tea extract
Study NCT00692497 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: one stop (Electronic standardised referrals and appointment bookings)
Description: The one stop strategy is a set of interventions directed at GPs referring to the University Hospital. The interventions include: Guidelines for referral, standardised electronic referrals, booking for outpatient surgery and a patient information form.
Study NCT02036541 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AqueSys XEN 45 Glaucoma Implant
Description: Placement of the AqueSys XEN 45 Glaucoma Implant in the study eye
Study NCT01179646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet
Description: Single dose crossover BE study
Study NCT01179646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet
Description: Single dose crossover BE study
Study NCT01075464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEGF0444A
Description: Intravenous escalating dose
Study NCT01075464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose
Study NCT01075464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenous repeating dose
Study NCT02548715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Study NCT02548715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02419651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Women will receive oral tramadol 100 mg 1 hour before the procedure
Study NCT02419651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Women will receive 100 mg diclofenac 1 hour before the procedure
Study NCT02419651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Women will receive a placebo 1 hour before the procedure
Study NCT01777139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retigabine IR
Description: Retigabine IR tablets will be available in 5 strengths: 50 mg, 100 mg, 200 mg, 300 mg, and 400 mg.
Study NCT04165135 — intervention group
Intervention type: DRUG
Intervention: Standard of Care for Haemophilia A
Description: There is no pre-determined studied medicinal product. Any treatment (including treatments started during the observational period) will be administered according to standard clinical practice, independently of participation in the current study, according to clinician's independent therapeutic decision.
Study NCT03813641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: Experimental: Oxaliplatin + Raltitrexed + Bevacizumab The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Raltitrexed (3mg/m2, intravenous drip for 15 minutes, d1)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
Study NCT03813641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Other: Oxaliplatin + Capecitabine + Bevacizumab The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Capecitabine (1000mg/m2 po. d1-14)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
Study NCT01891682 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Observational, Translational non-treatment study
Study NCT01281956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-00023
Description: PRX-00023 (Selective 5HT1A agonist)
Study NCT01281956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT02150681 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy
Description: This is an 8-week treatment for women with mood disorders. The focus of sessions 1 through 4 is to establish a foundation of mindfulness practice and bringing nonjudgmental awareness to the present moment, beginning with concrete targets of attention and moves to more emotionally challenging and abstract targets (e.g., depression-specific thoughts). Participants are guided to become aware of the automatic patterns of their minds and in such moments to return attention to thoughts, feelings and body sensations. Participants engage experientially with the ways in which thoughts and emotions become engaged with rumination. In sessions 5 through 8, participants learn to extend their basic mindfulness skills to become aware of relapse risk signs and develop prevention plans.
Study NCT02328794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-cigarette free access
Description: Participants in this arn will be given free access to e-cigarettes to help quit smoking
Study NCT02328794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-cigarette/NRT/Zyban/Chantix Choice
Description: Participants in this arn will be given free access to cessation aids to help quit smoking
Study NCT02328794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outcome Incentive arm
Description: Participants in this arm will be earn incentives across 6 months for verified abstinence.
Study NCT02328794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss framing incentive arm
Description: Participants in this arm will be told they have a pre-funded account with money that is theirs if they quit smoking.
Study NCT02328794 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will have access to information and advice on quitting smoking. This is a control and no actual intervention will be applied.
Study NCT02530918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-7080a
Description: 1.0, 2.0, or 4.0 mg administered by a 50 μL intravitreal (IVT) injection of solution
Study NCT02530918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.3 mg or 0.5 mg administered by a 50 μL IVT injection of solution
Study NCT02530918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: 0.3 mg or 0.5 mg administered by a 50 μL IVT injection of solution